Ionis Pharmaceuticals (IONS) Return on Capital Employed (2010 - 2026)
Ionis Pharmaceuticals (IONS) posted quarterly Return on Capital Employed of 20.45% for Q2 2026, down 713.0% year-over-year from 3.34% in Q2 2025, and down 60.82% quarter-over-quarter from 12.72% in Q1 2026.
Ionis Pharmaceuticals (IONS) Return on Capital Employed (2010 - 2026) Analysis & Trends
Ionis Pharmaceuticals' Return on Capital Employed history runs 17 years deep, the most recent figure standing at 20.45% for Q2 2026.
- In Q2 2026, Return on Capital Employed fell 713.0% year-over-year to 20.45%; the TTM figure through Jun 2026 stood at 20.45% (down 713.0% YoY), while the FY2025 annual figure was 15.38%, up 230.0% from the prior year.
- Return on Capital Employed for Q2 2026 stood at 20.45%, down from 12.72% in the prior quarter.
- The five-year high for Return on Capital Employed was 0.86% in Q3 2022, with the low at 21.8% in Q3 2023.
- The 5-year median for Return on Capital Employed is 15.17% (2024), against an average of 13.66%.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed surged 1342 bps in 2022, then sank 2266 bps in 2023.
- Ionis Pharmaceuticals' Return on Capital Employed stood at 18.93% in 2022, then advanced by 26 bps to 14.07% in 2023, then dropped by 24 bps to 17.38% in 2024, then rose by 12 bps to 15.29% in 2025, then sank by 34 bps to 20.45% in 2026.
- Business Quant data shows IONS's Return on Capital Employed at 20.45% in Q2 2026, 12.72% in Q1 2026, and 15.29% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Ionis Pharmaceuticals | 9.48 Bn | 7.43 Bn | 265.21 Mn | -20.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.45% |
| Mar 31, 2026 | -12.72% |
| Dec 31, 2025 | -15.29% |
| Sep 30, 2025 | -13.20% |
| Jun 30, 2025 | -13.31% |
| Mar 31, 2025 | -17.77% |
| Dec 31, 2024 | -17.38% |
| Sep 30, 2024 | -14.35% |
| Jun 30, 2024 | -15.07% |
| Mar 31, 2024 | -15.26% |
| Dec 31, 2023 | -14.07% |
| Sep 30, 2023 | -21.80% |
| Jun 30, 2023 | -17.86% |
| Mar 31, 2023 | -19.05% |
| Dec 31, 2022 | -18.93% |
| Sep 30, 2022 | 0.86% |
| Jun 30, 2022 | -0.37% |
| Mar 31, 2022 | 0.18% |
| Dec 31, 2021 | -1.33% |
| Sep 30, 2021 | -12.57% |